The Importance of Chemistry in Creating Well-Defined Nanoscopic Embedded Therapeutics: Devices Capable of the Dual Functions of Imaging and Therapy by Nyström, Andreas M. & Wooley, Karen L.
Published on the Web 06/15/2011 www.pubs.acs.org/accounts Vol. 44, No. 10 ’ 2011 ’ 969–978 ’ ACCOUNTS OF CHEMICAL RESEARCH ’ 969
10.1021/ar200097k &2011 American Chemical Society
The Importance of Chemistry in Creating
Well-Defined Nanoscopic Embedded
Therapeutics: Devices Capable of the Dual
Functions of Imaging and Therapy
ANDREAS M. NYSTR€ OM*
,† AND KAREN L. WOOLEY*
,‡
†The Swedish Medical Nanoscience Center, Department of Neuroscience,
Karolinska Institutet, SE-17177 Stockholm, Sweden, and
‡Department of
Chemistry,DepartmentofChemicalEngineering,TexasA&MUniversity,P.O.Box
30012, 3255 TAMU, College Station, Texas 77842-3012, United States
RECEIVED ON MARCH 30, 2011
CONSPECTUS
N
anomedicine is a rapidly evolving field, for
which polymer building blocks are proving
usefulfortheconstructionofsophisticateddevices
that provide enhanced diagnostic imaging and
treatment of disease, known as theranostics.
These well-defined nanoscopic objects have high
loading capacities, can protect embedded thera-
peutic cargo, and offer control over the conditions
and rates of release. Theranostics also offer ex-
ternal surface area for the conjugation of ligands to impart stealth characteristics and/or direct their interactions with biological
receptors and provide a framework for conjugation of imaging agents to track delivery to diseased site(s). The nanoscopic
dimensions allow for extensive biological circulation. The incorporation of such multiple functions is complicated, requiring
exquisite chemical control during production and rigorous characterization studies to confirm the compositions, structures,
properties, and performance.
We are particularly interested in the study of nanoscopic objects designed for treatment of lung infections and acute lung injury,
urinary tract infections, and cancer. This Account highlights our work over several years to tune the assembly of unique
nanostructures. We provide examples of how the composition, structure, dimensions, and morphology of theranostic devices can
tune their performance as drug delivery agents for the treatment of infectious diseases and cancer.
The evolution of nanostructured materials from relatively simple overall shapes and internal morphologies to those of
increasing complexity is driving the development of synthetic methodologies for the preparation of increasingly complex
nanomedicine devices. Our nanomedicine devices are derived from macromolecules that have well-defined compositions,
structures, and topologies, which provide a framework for their programmed assembly into nanostructures with controlled sizes,
shapes, and morphologies. The inclusion of functional units within selective compartments/domains allows us to create
(multi)functional materials. We employ combinations of controlled radical and ring-opening polymerizations, chemical
transformations, and supramolecular assembly to construct such materials as functional entities. The use of multifunctional
monomers with selective polymerization chemistries affords regiochemically functionalized polymers. Further supramolecular
assemblyprocesses inwater withfurther chemical transformations providediscrete nanoscopic objects within aqueoussolutions.
This approach echoes processes in nature, whereby small molecules (amino acids, nucleic acids, saccharides) are linked into
polymers(proteins,DNA/RNA,polysaccharides, respectively)andthenthosepolymersfold intothree-dimensional conformations
that can lead to nanoscopic functional entities.
Introduction
Well-defined nanoscopic objects that can be embedded
with therapeutics have great potential to protect the
therapeuticcargowithhighcapacityforloadingandcontrol
over the conditions and rates of release, while also offering
external surface area for conjugation of ligands to impart970 ’ ACCOUNTS OF CHEMICAL RESEARCH ’ 969–978 ’ 2011 ’ Vol. 44, No. 10
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stealth characteristics and/or direct their interactions with
biological receptors. The nanoscopic dimensions allow for
extendedbiologicalcirculationandprovideaframeworkfor
conjugation of imaging agents to track delivery to diseased
site(s). Incorporating such multiple functions is complicated,
requiring exquisite chemical control during production and
rigorous characterization studies to confirm the composi-
tions,structures,properties,andperformance.Directlinkage
to a particular disease is necessary to tune the chemical,
physical, and morphological features to gain access to the
disease site and deliver the cargo appropriately, for exam-
ple, extravascular, intracellular, and so forth.
Nanomedicine is a rapidly evolving field, for which poly-
mer building blocks are proving useful for the construction
of sophisticated devices, theranostics, that provide en-
hanced diagnostic imaging and treatment of disease. We
havespecialinterestsinthestudyofnanoscopicobjectsthat
are designed for treatment of lung infectious diseases,
urinary tract infections, acute lung injury, and cancer. Our
nanomedicine devices are derived from macromolecules
that have well-defined compositions, structures, and topol-
ogies, allowing for programmed assembly into nanostruc-
tures having controlled sizes, shapes, and morphologies.
The evolution of nanostructured materials from relatively
simpleoverallshapes andinternalmorphologiestothoseof
increasing complexity is driving the development of synthetic
methodologies that allow for the preparation of increas-
ingly complex nanomedicine devices. Moreover, the inclu-
sion of functional units within selective compartments/
domains is of great importance to create (multi)functional
materials. Combinations of controlled radical and ring-
opening polymerizations, chemical transformations, and su-
pramolecular assembly are employed to construct such
materials as functional entities. We employ a variety of multi-
functional monomers, together with selective polymeriza-
tionchemistries,toaffordregiochemicallyfunctionalizedpoly-
mers, and then further conduct supramolecular assembly
processes in water, often together with chemical transfor-
mations, to afford discrete nanoscopic objects within aqu-
eous solutions. This approach has similarities to the
processes of nature, whereby small molecules (amino acids,
nucleicacids,saccharides)arelinkedintopolymers(proteins,
DNA/RNA, polysaccharides, respectively) and then those
polymers fold into three-dimensional conformations that
can lead to nanoscopic functional entities. This Account will
highlight our work over several years to tune the assembly
of unique nanostructures, with examples of how their com-
positions, structures, dimensions, and morphologies can
tune their performance as theranostic agents for the treat-
ment of infectious diseases and cancer.
Tuning the Biological Interactions and
Biodistribution
As indicated by their name, theranostic nanoparticle sys-
tems(TNPs)aredesignedtofulfilltwoobjectives:therapeutic
delivery and diagnostic imaging. Parameters such as the
biodistribution (BioD), pharmacokinetics (PK), and pharma-
codynamics (PD) are inherently different between drug
delivery systems (DDS) and imaging systems. Nanoparticles
fordrugdeliverytypicallyexhibitextendedbloodcirculation
times in order to increase plasma concentration of the
pharmacologicallyactivesubstance,andalsotoexploitfully
the enhanced permeation and retention (EPR) effect or
ligand-mediatedtargeting,toreachfurtherincreasesinlocal
drug concentrations at disease sites. On the other hand,
nanoparticulate imaging agents often require a different set
of BioD, PK, and PD properties to operate with optimized
signal to background. Nanoscopic imaging agents are ad-
ministered to increase the signal-to-noise ratio in a specific
tissueandallowforadiagnosticimagetobeobtained.Inthe
case where the nanoparticle imaging agent is combined
with an “active” targeting ligand, the circulation half-life of
the construct becomes a critical parameter. In this setting, a
longer circulation will allow for accumulation (via more
circulation passes) at the target, but will require that the
nanoparticleultimatelyclearsinordertoreducebackground
(concentration) in the circulating blood to provide contrast.
Forsuccessful realizationoffunctionalTNPs,thismeansthat
these parameters of the device must compromise between
the optimum for drug delivery and that for diagnostic
imaging, which in turn requires flexible chemical synthesis
to systematically tailor the size, shape, charge, placement of
targeting ligands, degradation, drug loading and release
kinetics, and so forth.
In this context, shell cross-linked knedel-like nanoparti-
cles (SCKs) are versatile constructs for which a substantial
body of work has been performed to establish protocols for
controlling such parameters that are fundamental for nano-
medicalresearch,ingeneral,andtheranosticapplications,in
particular. In 2008, the Wooley lab developed a protocol for
designing SCK nanoparticles that exhibited tailored PK and
BioD.
1 The foundation for preparing these cross-linked NPs
was to utilize an amphiphilic block copolymer scaffold with
specific hydrophilic/hydrophobic ratios to render SCKs with
controlled core and shell dimensions (Figure 1). To tailor the
BioD and PK characteristics, these block copolymers wereVol. 44, No. 10 ’ 2011 ’ 969–978 ’ ACCOUNTS OF CHEMICAL RESEARCH ’ 971
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equipped with poly(ethylene glycol) (PEG) grafts of different
molecular weight and grafting density, combined with
64Cu
radiolabelsfordiagnosticimagingandfullBioDassessment.
Importantly, the grafting of PEG chains was performed on
the block copolymers prior to formation of the SCKs, to
achieve accurate determination and control over the graft-
ing density on the final nanostructures. It was observed that
fivePEGgraftsperblockcopolymergaveaPEGspacing,D,of
ca. 1 nm, capable of resisting adsorption of large and small
proteins
2,3andresultinginextendedbloodcirculationtimes.
This approach proved to be a much more efficient route to
obtaining NPs with high surface density of PEG and im-
provedstealthproperties,comparedtoatriblockcopolymer
of PEG-b-PAA-b-PS, even with longer PEG chain length,
which is a traditional way of obtaining stealthy micellar
nanostructures.
TheconceptoftargetingTNPstospecifictissueordisease
of choice is the fundamental premise of creating nanome-
dicines with high efficacy. The concept is not new; Paul
Ehrlish postulated the magic bullet concept in the early
1900s, and it is still a highly appealing idea.
4 The rationale
for creating such systems is simple: targeting drugs or
contrast can substantially increase the efficacy of treatment,
minimize the injected dose, overcome toxicity issues, provide
superiorcontrast(orsuperiorlocaltherapeuticconcentrations),
and allow for the intelligent design of personalized medicines
specifically designed for each patient subtype. However, there
areseveralconflictsthatresultfromthecompetingeffectsfrom
the use of ligands for active targeting by binding to biological
receptors, including alteration of the BioD
5 by hitting other
targets and immunogenic responses.
6
Ligand-mediated targeting of nanoparticles, or “active”
targeting, utilizes biomacromolecules, such as antibodies,
proteins, peptides, aptamers, or small molecular entities
attached to the surface of the nanoconstruct.
7 These ligands
are expected to bind overexpressed or specific receptors in
the tissue selected, followed often by receptor-mediated
endocytosis for transport into cells. Whether the ligand
targeting affects the PK or only the BioD is under debate.
Studies have shown that ligand-targeted liposomes do not
show a difference in the PK characteristics, but in the tumor
localization (BioD). Similarly, studies have indicated that
targeting NPs to a tumor has a more profound effect on
the local tumor distribution, where the targeting ligand acts
to distribute the NPs from the tumor stroma to an intracel-
lular localization.
8 Such effects are suggested to be an effect
FIGURE 1. SCKs having tailored in vivo behavior involve coupling onto polymer precursors to provide for chemical control and detailed
characterization. Reprinted with permission from ref 1. Copyright 2008 American Chemical Society.972 ’ ACCOUNTS OF CHEMICAL RESEARCH ’ 969–978 ’ 2011 ’ Vol. 44, No. 10
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ofthePEGylationofthesenanocarriers,prohibitingeffective
targetingdue tointerference withreceptor binding.
8Inmost
cases, the PEG shell is critical and cannot be excluded, as the
NP construct would otherwise rapidly activate mononuclear
phagocyte system (MPS) clearance mechanisms. However,
otherimportantfactorshavenotbeenstudiedingreatdetail
in vivo with respect to targeting, such as how particle
shape
9,10 and flexibility affect targeting with the same
ligand.
11,12 In such studies, nonbinding ligands of similar
shape,size,andcharge,forexample,scrambledpeptidesfor
peptide-based targeting ligands, must be used as controls.
In the case of SCKs of varying shapes, the inherent
carboxylic acid functionality of the hydrophilic poly(acrylic
acid)shell layerhasbeen utilized viathe formationofamide
bonds for cross-linking and the attachment of imaging
agents, PEGs for circulation enhancement, and targeting
components. Given that the SCK nanostructure contains
thousands of carboxylic acids or activated esters,
13 there
are many sites available, but the chemistry must be con-
ducted withcare to avoidlossof ligandbinding function. For
example, with peptides, this requires that the N-terminus is
the only amino group reacted, in order to avoid intra- and
intermolecular cross-linking. Conjugation of the protein
transduction domain of human immunodeficiency virus
type 1 Tat protein, a commonly employed cell penetrating
peptide sequence having the sequence GYGRKKRRQRRR,
onto spherical and cylindrical SCKs was accomplished by
using protected Tat peptides that could then be deprotected
(Figure 2).
11 It was found that smaller spherical Tat-SCKs (ca.
10 nm) were internalized by cells more rapidly than were
longer cylindrical (ca. 10 30 nm diameter but lengths of
g200 nm) nanostructures of the same composition. Differ-
ing degrees of Tat functionalization were also studied, for
which it was observed that the highest Tat peptide concen-
tration resulted in a 5-fold increase in cellular uptake, as
compared to the naked SCK. In contrast, the opposite
behavior was observed for spherical versus cylindrical SCKs
labeled with folate targeting ligands.
The folate receptor (FR), or membrane-associated folate-
binding protein, is one of the cellular transport systems that
binds folates with high affinity in the nanomolar range and
undergoes receptor-mediated endocytosis. Because the fo-
late receptor is well characterized and is overexpressed in
several cancer types with limited expression in normal
tissue, the FR is an attractive target for nanoparticles to treat
tumors.
14 Three studies have been reported for folate-
labeled SCKs: one that involved synthetic methodology
development,
15 another primarily in vivo oriented,
16 and
one in vitro focused.
12 In the first studies, folate was placed
ontheterminusofa1.6kDaPEGspacerthatwasconjugated
to the surface of pre-established SCKs, using their surface
availableCOOHgroups.Theseparticleswerefurtherlabeled
with fluorophores and
64Cu radioisotopes for in vitro and in
vivo studies.
16 The in vitro experiments indicated rapid
uptake of the folate-functionalized SCKs within 4 h at
37 C and only a surface bound fraction at 4 C, each of
FIGURE 2. SCKs having fluorescent labels and Tat peptides were prepared by conjugation of the active units onto pre-established SCKs. Reprinted
with permission from ref 11. Copyright 2008 American Chemical Society.Vol. 44, No. 10 ’ 2011 ’ 969–978 ’ ACCOUNTS OF CHEMICAL RESEARCH ’ 973
Well-Defined Nanoscopic Embedded Therapeutics Nystr€ om and Wooley
which could be blocked with the addition of free folic acid.
The BioD data in vivo indicated rapid and high MPS uptake
(53% in liver and spleen in 10 min), suggesting that the
folate-PEG did not provide a sufficient stealth layer and
should be complemented with unfunctionalized PEG chains
at a higher surface density. The BioD data showed no
evidence of the benefit of folate conjugation on in vivo
accumulation of nanoparticles in FR-overexpressing large
tumors, for which the EPR effect appeared to dominate SCK
uptake. However, there was some indication that smaller,
less developed tumors may have been targeted by folate
SCK-to-folate receptor interactions. In the most recent study,
the focus was on investigation of how the in vitro cellular
internalization was affected by the nanomorphology for
spherical versus cylindrical SCKs.
12 Contrary to the results
observed for the Tat-modified cylinders, it was found that
folate-functionalized cylinders were better candidates for
cell internalization than were folate-functionalized spheres.
This effect may be a result of receptor clustering, where the
cylinders are more capable of multivalent interactions due
to their (“longer”) size, and thereby triggering of multiple
receptor-mediated endocytotic processes.
In order to explore the use of diverse and biologically
complex targeting ligands, new conjugation methodologies
have been developed for SCKs. One such example is the
utilization of protected thiols, placed on the termini of PEG
grafts presented topologically on the outer surface of the
SCK nanoparticle, that can be deprotected/activated for
further conjugation with thiol- or maleimide-containing
targeting groups to form reversible disulfide or thioether
linkages, respectively.
17 These SCKs were shown to
have high thiol reactivity and could be used to attach the
model protein albumin with good coupling efficacy. The
thiol maleimide Michael addition or furan maleimide
Diels Alder conjugation are highly attractive conjugation
strategies for the attachment of antibodies, since site-specific
Fc-introduction of maleimide groups on antibodies is well
established and demonstrated on nanoparticles to maintain
binding efficacy in vitro.
18 Although not tested yet on the SCK
scaffold, thiol groups can also be utilized in high yielding
thiol ene couplings.
19
In our experience with SCK nanoparticles, it has been
clear that achieving efficient and quantifiable targeting
(including results not published) is indeed difficult. Our
hypothesis is that the ligand presentation is not optimum
in many targeted NPs and that the chemical design of the
carriersmustbemoresophisticated.Iftheligandisplacedon
a spacer unit such as PEG, the remaining PEG (necessary for
circulation enhancement) must be of sufficiently shorter
length in order not to interfere with binding to the receptor.
In addition, covalent attachment of the ligand to the spacer
molecule must be such that the binding characteristics are
not hampered. In the antibody, antibody fragment or pro-
tein case, this requires site specific modification reactions,
andtheemploymentofrapid,efficientandorthogonal(REO)
ligation methods for covalent attachment to NPs.
20 With
small molecule ligands, control is achieved more easily.
Similarly, the nature of the spacer is worthwhile to consider,
as one can imagine that a more rigid spacer with longer
persistencelengthmaywellpresentthetargetingligandina
better conformation for receptor interaction. Jiang and Cao
have demonstrated that zwitterionic polymers offer advan-
tages over PEG for inhibition of protein adsorption,
21 and
these polymers are quite attractive for SCKs because they
also offer functionalizability. Strategies that employ cleava-
ble or other linkages to bury the ligands until the target site
(e.g., tumor) is reached may offer advantages for cell uptake
and so on, but they fail to address the challenges associated
with getting to that site.
Control over the route of administration of the nanocon-
struct is a highly attractive means by which to exploit the
advantage that the specific organ provides combined with
selected targeting approaches. For example, localized ther-
apy of urinary tract or lung infections may be achieved via
catheter delivery to the bladder or inhalation delivery of
aerosols to the lung, respectively. We are currently devoting
significant efforts toward the treatment of infectious dis-
eases by the direct administration of antimicrobial-loaded
SCKs
22 to the lung and bladder. Preliminary in vivo tests
have shown outstanding performance. Nasal delivery has
beensuggestedasanotherdirectadministrationmethodfor
achieving delivery in the brain, utilizing the olfactory path-
way where the nervous system is in contact with the
surrounding environment.
23
A directed approach to actively target tissues in vivo,
without the use of targeting ligands, utilizes superparamag-
netic nanoparticles together with an external magnetic field
to localize the drug carrier to the tissue of choice.
24
This method requires that the diseased tissue is known
and can be visualized for guidance procedures. The concept
is indeed interesting for some clinical applications, but
several problems still exist, such as scaling up from the
animal models, embolization of blood vessels in the area,
controlling the magnetic field geometry, and dealing with
biological clearance issues for nondegradable inorganic
nanoparticles.974 ’ ACCOUNTS OF CHEMICAL RESEARCH ’ 969–978 ’ 2011 ’ Vol. 44, No. 10
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Imaging Modalities
Positron emission tomography is a highly sensitive imaging
modality, with which we have had great success in tracking
SCKs in vivo. As with the PEGylation of SCKs, it was found
that conjugation of chelators for the PET-active radionu-
clides was best performed onto the polymer precursors to
allow for efficient coupling and accurate quantification and
characterization studies to be performed.
25 Earlier attempts
to couple chelators and perform radiolabeling onto pre-
established SCKs experienced difficulties.
26 The advantages
of nanoparticles for PET imaging applications has already
been reviewed.
27 We have also begun developments of
SCKs toward optical imaging modalities.
28,29
Magnetic resonance imaging (MRI) is powerful in its ability
to visualize soft tissues. Nanoparticles for MRI include both T1
(positive contrast) based agents, such as NPs containing rare
earth metals, Gd
3þ, and others, as relaxation aids, or super-
paramagnetic NPs, such as SPIONs for T2 (negative contrast)
weighted imaging. Apart from these standard MRI applica-
tions, NPs for T1 imaging of other natural isotopes such as
19F,
31P,
13C,
14N, and others have been developed. Of these
isotopes,
19Fnucleiareattractiveduetothelackofbackground
in normal tissue (only low levels in teeth and bone), good
biocompatibility, sensitive chemical shift, high gyromagnetic
ratio, and high natural abundance. We have explored the use
of nanoscale
19F-MRI agents capable of both chemotherapeu-
tic delivery and
19F-MRI either in the form of hyperbranched
polymer micelles
30,31 or SCKs.
32 Fluorinated hyperbranched
polymer micelles were initially investigated, since it was hypo-
thesized that the multicompartmental amphiphilic structure of
the polymer scaffold would allow sufficient mobility for the
fluorinatedcomponenttoachievebeneficialrelaxationkinetics
for imaging while also providing nanoscopic compartments
for chemotherapeutic loading via hydrophobic interactions.
We found that this design strategy indeed produced nanopar-
ticles with one narrow
19F signal and much better T1 and
slightly better T2 relaxation times for imaging applications
comparedtoperfluorocrownether(PFCE).
31Invitroevaluation
indicated low toxicity and good biocompatibility of the NP
itself,buttheabsolutefluorineconcentrationwastoolowforin
vivo imaging.
30 To overcome the limitations in fluorine con-
centration that the hyperbranched fluoropolymer system ex-
perienced, we also explored fluorinated SCKs, as these
structureshaveshownhighloadingcapacitiesforhydrophobic
chemotherapeutics.
33,34 SCKs with fluorinated hydrophobic
cores were further loaded with PFCEs having 15 chemically
equivalent fluorine atoms. Despite the high fluorine
concentration, unfortunately, it was found that the hydropho-
bic core restricted the mobility of the PFCE to such an extent
thatthesignalwasnotdetectablewithoutplasticizingthecore.
Therapeutic Cargo
SCKs have been investigated as carriers of therapeutics
directed against three main applications: cancer,
33 35 in-
fectious diseases,
22 and acute lung injury. In drug delivery
applications, SCKs are attractive candidates due to their
stability, high loading capacity, and the broad tunability of
composition, structure, dimension and morphology. Our
interest has been to craft the SCK to optimize drug loading
capacity and control the release kinetics. The amphiphilic
core shell morphology is taken advantage of, and we have
performed studies that have involved packaging of thera-
peutics in the core, at the core shell interface and in the
shell, while tuning the compositions, properties, and dimen-
sions of each.
In one case, we probed effects of amorphous versus
semicrystalline core domains, with the intention being to
trap doxorubicin, an anthracycline antibiotic and a very
common chemotherapeutic agent used in the treatment of
many cancer types, within the semicrystalline core at room
temperature and promote their release at physiological
temperature.
33,35 We found that high loading concentra-
tions (20% w/w) of doxorubicin in SCKs could be achieved
with both amorphous and crystalline nanoparticle cores,
due to the combined favorable hydrophobic and π π inter-
actions for doxorubicin with the cores and ionic interactions
with the SCK shells. The drug-loaded SCKs were found to
kill U87 cancer cells via apoptosis in vitro, while no
negative effect on cell viability was found from the SCKs
themselves.
We also conducted an in-depth study of the effects of
the particle dimensions, including overall diameter, core
diameter, and shell thickness, on the drug release kinetics.
Effects of the nanoparticle composition were held constant, by
employing SCKs constructed from a single type of amphiphilic
diblock copolymer (Figure 3). A series of four SCK nanoparticle
samples, ranging in number-average hydrodynamic diameter
from 14 to 30 nm, was prepared from four block copolymers
havingdifferentrelativeblocklengthsandabsolutedegreesof
polymerization. Their shell-to-core volume ratio showed im-
pact on the rates and extents of release of DOX, with the
volume occupied by the poly(acrylic acid) shell relative to the
volumeoccupiedbythepolystyrenecorecorrelatinginversely
with the diffusion-based release of DOX.Vol. 44, No. 10 ’ 2011 ’ 969–978 ’ ACCOUNTS OF CHEMICAL RESEARCH ’ 975
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We have also investigated the SCK scaffold for the
delivery of silver-based antimicrobial agents, which are of
interest for treating bacterial infections in the lung and
bladder. Silver-based agents are interesting as antibacterial
therapeutics because toxicity to human tissues is low and
bacteria rarely develop resistance against silver-based
agents. The SCKs were either loaded with Ag
þ within the
framework of the poly(acrylic acid) shell or silver carbene
complexes that were expected to reside near the core shell
interface (Figure 4). The SCKs were found to have high
loading capability and sustained release of the silver agents
overthecourseofseveraldays.Thesesilver-containingSCKs
were found to be effective inhibitors of infection in vitro
against urinary isolates of Escherichia coli and respiratory
isolates of Pseudomonas aeruginosa.
Using nature as a guide, SCKs have been prepared as
synthetic analogs of histones,
36 of ca. 10 nm diameter and
carrying positive surface charge character, and studied for
their ability to package nucleic acid-based materials
(plasmid DNA, oligoDNA, peptide nucleic acids, siRNA).
36 39
Ultimately, the interest is in the delivery of nucleic acids for
molecular recognition of mRNA overexpressed in sites of
acute lung injury, to allow for diagnostic imaging and/or
therapy. A current target is the mRNA of inducible nitric
oxide synthase; however, much work remains to advance
from promising in vitro cell transfection results to a working
system in vivo.
Degradability
For SCKs described so far, degradability has not been re-
garded as the primary objective, mainly because the phy-
siochemical, in vitro, and in vivo studies have been time-
consuming,andarapidlydegradableNPsystemwouldpose
challenges with study prior to the disintegration of the
controlled morphology. However, to successfully utilize
nanoparticle constructs for therapeutic delivery in the clinic,
clearance of the NP or its building blocks must be assured,
while also avoiding toxic effects from the particles and
degradation products. The metabolic fate of the nanoparti-
cle and the single and multiple dose toxicity must be
investigated, along with many other factors such as clear-
ance routes.
For SCKs, both degradability of the cross-links stabilizing
the micelles
40 and the polymer scaffold used for construc-
tion have been studied.
41 Creating pH-degradable cross-
links in the nanostructure is an interesting design feature
that would allow degradability to be easily incorporated in
any SCK construct, and result in the rapid disassembly of the
nanoparticle. Provided that the constituent building blocks
are small enough to allow for renal clearance, accumulation
of the nanoparticle or its components can be avoided. To
FIGURE 3. SCKs as carriers of doxorubicin, with the ability to tune the compositions and dimensions of the core and shell domains independently.
Reprinted with permission from ref 34. Copyright Elsevier 2011.
FIGURE4. Loadingofsilver-basedantimicrobialagentswithintheshell
or core shell interface of SCK nanoparticles. Reprinted with permission
from ref 22. Copyright Royal Society of Chemistry 2010.976 ’ ACCOUNTS OF CHEMICAL RESEARCH ’ 969–978 ’ 2011 ’ Vol. 44, No. 10
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demonstrate hydrolytic cleavage of degradable cross-links,
a self-reporting cross-linking system was utilized, having a
UV vis reporter unit that was released upon hydrolysis of
acetal linkages (Figure 5). This system allowed for real-time
monitoring of the degradation process in vitro via quantifi-
cation of the released 4-methoxy-1-naphthaldehyde. It was
found that the half-life of the neat cross-linker at pH 7.4 was
29 h and that incorporation of the cross-linker in the SCK
nanostructurereducedthehalf-lifetoca.1.5h;atpH5.0,the
half-life dropped to 13 min. The rapid acceleration of hydro-
lysisintheSCKshellsuggestsuseinvivoforboththerapeutic
delivery and diagnostic imaging, as localization in diseased
tissue should occur within a few circulation passes (seconds
tominutes),followedbydegradationofcross-linkstorelease
therapeutics and clear the background NP in circulation.
Furthermore,thedecreasedhalf-lifeunderacidicconditionswill
promote accelerated degradation and release in cells or tumor
environment. Further, degradability of the polymer building
blocks can be advantageous for nanoparticles that are com-
posed of larger polymer chains, or for applications where
complete degradation of the NP systems is desired.
41 43
Conclusions/Outlook
The primary advantage of theranostics is that they are not
limitedtotherapyorimaging,butallowforcombinations,to
give coincident diagnostic information plus delivery of ther-
apeutics.Nanoscopicobjectsserveasscaffoldsthathavethe
optimum, intermediate size between the molecular level
and microscopic materials, to provide domains for high
capacitiesoftherapeutic loadingandsitesforlabeling,while
also having high surface areas for the presentation of
targeting ligands. Although imaging of the nanoscopic de-
vice and delivery of a molecular therapeutic does not offer
dual tracking of each independently, having information
abouttheconditionsunderwhichthetherapeuticisreleased
and the ability to monitor the nanostructure gives some
indication of the theranostic benefit. However, if each is
labeled separately or if the nanoscopic diagnostic agent is
the therapeutic, then dual tracking is built in. This result
occurs with labeled protein or antibody therapeutics, but
could also be made to be true, for instance, if synthetic
nanomaterials could be advanced to the point of offering
therapeutic benefit directly, by triggering biological responses
without the need for release of small molecule therapeutics.
We are particularly interested in studying hierarchically as-
sembled nanomaterials that have complex structures and
functions,
44,45 and can trigger unique biological responses or
carry multiple diagnostic and therapeutic payloads.
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